Purpose: To evaluate the acute changes in intraocular cytokines after intravitreal
bevacizumab (IVB) in proliferative diabetic retinopathy.
Design: Prospective, open-label, controlled, randomized interventional clinical trial.
Participants: Twenty eyes of 28 consecutive patients who are scheduled for pars plana
vitrectomy (ppV) for proliferative diabetic retinopathy were prospectively enrolled.
Methods: All patients were randomly assigned to receive IVB either at 2 or 7 days before ppV.
Aqueous humor samples were taken from anterior chamber just before IVB and at the time of
surgery. Multiplex cytokine array were used to assay various cytokines